Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07673016 · ClinicalTrials.gov registry record
Specimen Collection for Validation of UroAmp: A Next Generation Sequencing Platform for Detection and Surveillance of Bladder Cancer
A clinical trial, sponsored by Convergent Genomics.
- Recruiting
- Registry status
- 2,500
- Enrollment target
NCT07673016 is a clinical trial that is actively recruiting participants, run by Convergent Genomics. The registered enrollment target is 2,500 participants.
The verdict
NCT07673016 is actively recruiting participants, sponsored by Convergent Genomics.
- RECRUITING
- Registry status
- 2,500 participants
- Enrollment target
Study Summary
This is a prospective, multicenter observational study designed to collect urine and tumor biospecimens and associated clinical data from patients undergoing evaluation, treatment, or surveillance for urothelial carcinoma.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2,500 participants |
| Start Date | 2019-10-15 |
| Est. Completion | 2034-12 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07673016
The ClinicalTrials.gov registry entry for NCT07673016 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 2,500 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Convergent Genomics, which has 2 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 0 interventions.
NCT07673016 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07673016 about?
NCT07673016 is a clinical study titled "Specimen Collection for Validation of UroAmp: A Next Generation Sequencing Platform for Detection and Surveillance of Bladder Cancer". This is a prospective, multicenter observational study designed to collect urine and tumor biospecimens and associated clinical data from patients undergoing evaluation, treatment, or surveillance for urothelial carcinoma.
What is the current status of trial NCT07673016?
This trial is currently recruiting. The enrollment target is 2,500 participants. The study started on 2019-10-15. Estimated completion is 2034-12.
Who is sponsoring clinical trial NCT07673016?
This trial is sponsored by Convergent Genomics, which has 2 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.